Percheron Therapeutics (AU:PER)
ASX:PER
Top Page
Percheron Therapeutics
(Sydney:PER)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:N/ADate:01/04/26
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and accelerating cash burn), partially offset by low leverage on the balance sheet. Valuation is constrained by negative earnings and no dividend data, while technical analysis contributes limited insight due to missing indicators.
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.61M
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,522,412,700
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$2.15M
Percheron Therapeutics Business Overview & Revenue Model
Company Description
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the...
How the Company Makes Money
null...
Percheron Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.97K | -67.98K | -79.42K | -95.20K | -89.22K | -103.32K |
| EBITDA | -10.94M | -16.27M | -11.84M | -13.25M | -7.52M | -8.58M |
| Net Income | -9.49M | -14.92M | -11.92M | -11.38M | -5.81M | -8.06M |
Balance Sheet | ||||||
| Total Assets | 7.90M | 12.44M | 14.53M | 12.84M | 22.44M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 4.46M | 10.17M | 11.87M | 10.97M | 19.23M | 6.02M |
| Total Debt | 10.68K | 25.86K | 39.87K | 142.10K | 227.40K | 306.85K |
| Total Liabilities | 763.70K | 2.43M | 5.17M | 2.87M | 1.30M | 1.27M |
| Stockholders Equity | 7.14M | 10.00M | 9.36M | 9.98M | 21.14M | 5.73M |
Cash Flow | ||||||
| Free Cash Flow | -9.78M | -15.65M | -10.12M | -8.18M | -7.81M | -5.84M |
| Operating Cash Flow | -9.78M | -15.64M | -10.12M | -8.15M | -7.81M | -5.83M |
| Investing Cash Flow | -3.08M | -7.24K | -3.61K | -29.29K | -3.91K | -8.35K |
| Financing Cash Flow | -70.82K | 13.95M | 11.02M | -85.30K | 21.02M | 7.80M |
Percheron Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$25.18M | -12.06 | 7.64% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$17.68M | -4.15 | -29.05% | ― | 45.30% | -24.18% | |
43 Neutral | AU$7.61M | -0.79 | -110.74% | ― | ― | ― | |
43 Neutral | AU$19.73M | -2.87 | 4388.00% | ― | -47.30% | 82.53% | |
39 Underperform | AU$9.58M | 0.07 | 93.89% | ― | -26.49% | 61.72% |
* Healthcare Sector Average
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:CAN
Cann Group
0.01
-0.02
-62.96%
AU:LGP
Little Green Pharma Ltd.
0.10
-0.02
-19.17%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-15.00%
AU:IDT
IDT Australia Limited
0.04
-0.04
-48.81%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-39.68%
Percheron Therapeutics Corporate Events
Percheron Therapeutics Launches Discounted Entitlement and Shortfall Offer
Mar 16, 2026
Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer, allowing eligible shareholders to subscribe for two new shares for every five existing shares at an issue price of $0.005, with one free attaching option for every ...
Percheron Therapeutics Plans Issue of 50 Million Unquoted Options
Mar 16, 2026
Percheron Therapeutics has notified the ASX of a proposed issue of up to 50 million unquoted options as part of a placement or similar capital initiative. The options will be exercisable at $0.01 per share and will expire two years from the date o...
Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX
Mar 16, 2026
Percheron Therapeutics has announced a proposed non-renounceable pro rata offer to existing shareholders, comprising up to 434,975,053 new fully paid ordinary shares and 217,487,526 unquoted options exercisable at A$0.01 within two years of issue....
Percheron Updates Timetable for $2.2m Entitlement Offer Ahead of 2026 Trials
Mar 16, 2026
Percheron Therapeutics has updated the timetable for its previously announced non-renounceable entitlement offer, which aims to raise up to approximately $2.2 million. The revised schedule adjusts the ex date and record date, and sets out key mile...
Percheron Therapeutics Launches Pro Rata Rights Offer at Discounted Issue Price
Mar 15, 2026
Percheron Therapeutics Limited has released a prospectus for a two-for-five pro rata non-renounceable rights offer, allowing eligible shareholders to subscribe for new shares at $0.005 each, with one new option issued for every two new shares take...
Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial
Mar 15, 2026
Percheron Therapeutics has launched a 2-for-5 non-renounceable entitlement offer to raise up to approximately $2.2 million at $0.005 per share, a discount of about 20% to its recent volume-weighted average price, with one free attaching option (ex...
Percheron Therapeutics Plans Issue of 13.75 Million Unquoted Options
Mar 13, 2026
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 new unquoted options as part of a placement or similar capital initiative. The options will have an exercise price of A$0.01 and a two-year term from the issue ...
Percheron Therapeutics Narrows Half-Year Loss but Sees Net Assets Per Share Fall
Feb 26, 2026
Percheron Therapeutics Limited reported a significantly reduced half-year loss for the period ended 31 December 2025, with net loss after tax falling 64% to $3.1 million from $8.5 million a year earlier. The company held cash reserves of $4.46 mil...
Percheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data
Jan 30, 2026
Percheron Therapeutics has reported final data from a completed phase I clinical trial of its lead candidate HMBD-002, showing a favourable safety profile with few severe treatment-related adverse events and early signs of anti-tumour activity, in...
Percheron Therapeutics Director Increases On-Market Shareholding
Dec 29, 2025
Percheron Therapeutics has disclosed a change in director Ben Gil Price’s holdings, following his on-market purchase of 2 million fully paid ordinary shares on 22 December 2025 for approximately A$17,220, increasing his total shareholding to...
Percheron Therapeutics Director James Garner Increases Shareholding via On-Market Purchase
Dec 23, 2025
Percheron Therapeutics has disclosed that director James Garner increased his direct holding in the company by purchasing 1 million fully paid ordinary shares on-market between 17 and 19 December 2025 for a total consideration of $8,500. Following...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.